0220: Effectiveness of ezetimibe on blood lipids in real life clinical practice

详细信息    查看全文

• 作者：Michel Rossignol⁽¹⁾ ; Jean Ferriè ; res⁽²⁾ ; Jean Dallongeville⁽³⁾ ; Lucien Abenhaim⁽⁴⁾ ; Lamiae Grimaldi Bensouda ; ⁽⁵⁾ ; ^{lamiae.grimaldi@la-ser.com" class="auth_mail" title="E-mail the corresponding author} ; Eze Study Group⁽⁵⁾
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：8
• 期：1
• 页码：95
• 全文大小：61 K

文摘

EZE cohort was a 48-month prospective, nationwide study conducted between 2008 and 2013 in Franceat the request of the French Haute Autorité de Santé. Its objective was to assess the real life use and impact of the drug on lipid lowering. Over 700 physicians (94% general practitioners and 4% cardiologists recruited and described 3,395 eligible adult patients who had initiated ezetimibe treatment for no longer than three months, of which 3,215 (94.7%) were entered in the analyses. Patients were naturalistically followed up to 4 years without any visits formally planned. Blood lipids were reported by physicians every twelve months and lipid lowering medicines utilization every six months with patient’s telephone interviews between each physician’s visit.

9 314 person-years of follow-up were accumulated. At inclusion, patients were 61.5 year-old on average (standard deviation (SD): 10.7) and 54.6% were males. Classified by CV risk categories were for primary prevention 29.3% low, 32.4% moderate and 11.4% high, and 26.9% secondary prevention.

Type of ezetimibe exposure at inclusion was 33.1% monotherapy, 13.2% ezetimibe added to a statin, and 53.7% fixed association ezetimibe – simvastatin. Exposure to ezetimibe has been very stable during follow-up of the cohort with treatment interruption rate of 12.5 per 100 person-years of followup. LDL-C was 4.1mmol/L (SD: 1.1) at baseline and decreased by 23.8% (SD: 28.8) in the first 12 months, reaching –27.3% (SD: 28.3) at 48 months. Adjusting for baseline clinical characteristics and risk factors, interruption of lipid lowering treatment at least once during the follow-up was associated with a lower probability for the LDL-C to progress to the lower tertile (OR: 0.38, 95% confidence interval: 0.31 – 0.45). In this population with incident exposure to ezetimibe LDL-C decreased by one quarter in the first year and remained stable over the four-year follow-up.